Replimune, Inc.
17
7
12
0
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 85/100
17.6%
3 terminated/withdrawn out of 17 trials
0.0%
-86.5% vs industry average
6%
1 trials in Phase 3/4
0%
0 of 0 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (17)
Phase II Study of RP2 as Immunoprevention in High-Risk Oral Precancerous Disease
Role: collaborator
Study to Investigate the Efficacy and Safety of RP1 in Adult Patients With Organ Transplants and Advanced Skin Malignancies
Role: lead
RP1 in Primary Melanoma to Reduce the Risk of Sentinel Lymph Node Metastasis
Role: collaborator
A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma
Role: lead
Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCC
Role: lead
Intratumoral Vusolimogene Oderparepvec (VO) in Combination With Pembrolizumab for Angiosarcoma
Role: collaborator
VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs [IGNYTE-3]
Role: lead
Study of RP2 Monotherapy and RP2 in Combination With Nivolumab in Patients With Solid Tumors
Role: lead
Study of RP3 Monotherapy and RP3 in Combination With Nivolumab in Patients With Solid Tumours
Role: lead
Study of RP1 Monotherapy and RP1 in Combination With Nivolumab (IGNYTE)
Role: lead
RP2/RP3 in Combination With Atezolizumab and Bevacizumab for the Treatment of Patients With CRC
Role: lead
A Study to Assess the Long-term Safety Outcomes in Patients Previously Treated With RP1, RP2, or RP3
Role: lead
Neoadjuvant Intra-tumoral RP2 and FLOT in Gastroesophageal Adenocarcinoma
Role: collaborator
An Expanded Access Program for VO (RP1) in Combination With Nivolumab in Patients With Advanced Melanoma
Role: lead
"neoBREASTIM": Atezolizumab Plus RP1 Oncolytic Immunotherapy in the NeoAdjuvant Setting of Triple-Negative Breast Cancer
Role: collaborator
Study of RP3 in Combination With Nivolumab and Other Therapy in Patients With Locoregionally Advanced or Recurrent SCCHN
Role: lead
Study Evaluating Cemiplimab Alone and Combined With RP1 in Treating Advanced Squamous Skin Cancer
Role: lead
All 17 trials loaded